<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00947882</url>
  </required_header>
  <id_info>
    <org_study_id>FE200486 CS36</org_study_id>
    <secondary_id>2009-012325-11</secondary_id>
    <secondary_id>104367</secondary_id>
    <nct_id>NCT00947882</nct_id>
  </id_info>
  <brief_title>A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)</brief_title>
  <acronym>DELUTS</acronym>
  <official_title>A Dose-Finding, Multi-Centre, Double-Blind, Randomised, Parallel, Placebo-Controlled Trial to Investigate Efficacy and Safety of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A dose-finding, multi-centre, double-blind, randomised, parallel, placebo-controlled trial to
      investigate efficacy and safety of degarelix in men with lower urinary tract symptoms (LUTS)
      associated with benign prostatic hyperplasia (BPH)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in International Prostate Symptom Score (IPSS)</measure>
    <time_frame>From Baseline to Month 3 after Dosing</time_frame>
    <description>This outcome measure was used to assess the dose-response of the 3 degarelix dose groups in terms of severity of lower urinary tract symptoms (LUTS) and progress of the disease process, versus the placebo group. One treatment month equals 28 days.
The IPSS questionnaire is a tool commonly used to assess the severity of LUTS, and to monitor the progress of the symptoms during treatment. It contains 7 questions regarding incomplete emptying, frequency, intermittency, urgency, weak stream, straining, and nocturia. Each question is assigned a score of 0-5 (i.e. minimum total score is 0 and the maximum score is 35), where &quot;0&quot; corresponds to a response of &quot;not at all&quot; for the first six symptoms and &quot;none&quot; for nocturia, and &quot;5&quot; corresponds to a response of &quot;almost always&quot; for the first six symptoms and &quot;5 times or more&quot; for nocturia. The IPSS also includes a question to evaluate a patient's quality of life in relation to his urinary symptoms, which is not included in the total IPSS score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change in IPSS</measure>
    <time_frame>From Baseline to Month 4, Month 5 and Month 6 after Dosing</time_frame>
    <description>This secondary outcome measure was used to assess the maintained dose-response of the 3 degarelix dose groups in terms of severity of LUTS and progress of the disease process, versus the placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Odds Ratio (as Compared to Placebo) of Treatment Response in IPSS</measure>
    <time_frame>At Month 3, Month 4, Month 5 and Month 6 after Dosing</time_frame>
    <description>A 3-point reduction in IPSS score compared to baseline is defined as a clinically meaningful treatment response. Percentage of participants who met criteria for a clinically meaningful treatment response and odds ratios of treatment responses between each degarelix dose group and the placebo group are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percentage Change in Total Prostate Volume (TPV)</measure>
    <time_frame>From Baseline to Month 3 and Month 6 after Dosing</time_frame>
    <description>TPV was measured directly by standardised trans-rectal ultrasound (TRUS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Maximum Urinary Flow (Qmax)</measure>
    <time_frame>From Baseline to Month 3 and Month 6 after Dosing</time_frame>
    <description>Urinary flow rate (mL/second) was measured using uroflowmetry performed according to the recommendation from the International Continence Society (ICS).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">404</enrollment>
  <condition>Lower Urinary Tract Symptoms (LUTS)</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Degarelix 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Degarelix 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Degarelix 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Mannitol 50 mg/mL solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix 10 mg</intervention_name>
    <description>10 mg degarelix, 40 mg/mL solution</description>
    <arm_group_label>Degarelix 10 mg</arm_group_label>
    <other_name>FE200486</other_name>
    <other_name>Firmagon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix 20 mg</intervention_name>
    <description>20 mg degarelix, 40 mg/mL solution</description>
    <arm_group_label>Degarelix 20 mg</arm_group_label>
    <other_name>FE200486</other_name>
    <other_name>Firmagon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix 30 mg</intervention_name>
    <description>30 mg degarelix, 40 mg/mL solution</description>
    <arm_group_label>Degarelix 30 mg</arm_group_label>
    <other_name>FE200486</other_name>
    <other_name>Firmagon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent obtained before any trial-related activity is performed

          -  Men, aged 50 or older

          -  Clinical signs and symptoms of BPH for ≥6 months

          -  Moderate to severe LUTS at screening, as defined by International Prostate Symptom
             Score (IPSS) ≥13

          -  An IPSS QoL score of ≥3 at screening

          -  Prostate specific antigen (PSA) at screening ≤10 ng/mL (responsibility of the
             Investigator to rule out prostate cancer when PSA is &gt;4 ng/mL, except in the USA where
             patients with a PSA &gt;4 and ≤10 ng/mL should undergo a prostatic biopsy or have a
             negative prostatic biopsy within 12 months prior to participation in the trial)

          -  Maximum urinary flow (Qmax) ranging between 5 to 15 mL/second with a minimum voided
             volume &gt;125 mL at screening

        Exclusion Criteria:

          -  Post void residual volume (PVR) &gt;250 mL

          -  Stone in the bladder or urethra causing symptoms

          -  Acute or chronic prostatitis

          -  Interstitial cystitis / painful bladder syndrome

          -  Acute or recurrent urinary tract infections

          -  History of acute urinary retention (AUR)

          -  Lower urinary tract instrumentation (including prostate biopsy) within 30 days of
             dosing at Visit 2

          -  Clinical evidence of any of the following urinary tract conditions:

               1. Mullerian duct cysts

               2. Atonic, decompensated, or hypocontractile bladder

               3. Detrusor-sphincter dyssynergia (contraction of the detrusor without sphincter
                  relaxation)

          -  History of any of the following pelvic conditions:

               1. Pelvic surgery or any other pelvic procedure, including radical prostatectomy,
                  pelvic surgery for removal of malignancy, or open lower colonic or rectal surgery

               2. Pelvic radiotherapy

               3. Any prior surgical procedure of the urinary tract, including minimally invasive
                  LUTS/BPH therapies

               4. Lower tract malignancy or trauma

          -  Clinically significant microscopic haematuria at screening

          -  History of significant renal insufficiency, defined as receiving renal dialysis or
             having an estimated creatinine clearance &lt;30 mL/minute at screening

          -  Systolic blood pressure &gt;180 or &lt;90 mmHg or diastolic blood pressure &gt;110 or &lt;50 mmHg
             at screening or malignant hypertension

          -  Any causes other than BPH, which may affect evaluation of symptoms of urine flow (e.g.
             neurogenic bladder, bladder neck contracture, urethral stricture, and bladder
             malignancy) as judged by the Investigator

          -  Use of any prohibited therapies

          -  Elevated liver function tests at screening:

               1. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline
                  phosphatase (ALP) &gt;2 times the upper limit of normal

               2. Total bilirubin &gt;1.5 times the upper limit of normal

          -  QTc interval on the screening ECG &gt;450 ms, or a family history of long QT syndrome

          -  Any clinically significant disorder (other than BPH) including, but not limited to,
             renal, haematological, gastrointestinal, endocrine, cardiac, neurological, or
             psychiatric disease, or any other condition, which may affect the patient's health or
             the outcome of the trial as judged by the Investigator

          -  Diagnosed cancer within the last 5 years except for adequately managed basal cell
             carcinoma and squamous cell carcinoma of the skin

          -  History of severe untreated asthma, anaphylactic reactions, or severe urticaria and/or
             angioedema

          -  Mental incapacity or language barrier precluding adequate understanding or
             co-operation

          -  History or current evidence of drug, alcohol, or substance abuse within 6 months prior
             to screening

          -  Hypersensitivity towards any component of the investigational medicinal product (IMP)

          -  Previous participation in any degarelix trial
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urology Centers of Alabama, PC</name>
      <address>
        <city>Homewood</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Clinical Research Inc</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Professional Research</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genitourinary Surgical Consultants</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Associates , PC</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Medical Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winter Park Urology Associates</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinellas Urology Inc</name>
      <address>
        <city>St Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Urology Partners</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College New York Presbyterian</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hudson Valley Urology, PC</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Patient Priority Clinical Sites, LLC</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Middelheim Antwerp</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Can-Med Clinical Research Inc</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Steinhoff Clinical Research</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Male/Female Health and Research Centre</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bramalea Medical Centre</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brandford Urology Research</name>
      <address>
        <city>Brantford</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guelp Urology</name>
      <address>
        <city>Guelph</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Applied Urological Research</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Female/Male Health Centres</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mahoney Medicine Professional Corporation</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Todd Webster Ontario Inc</name>
      <address>
        <city>Owen Sound</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anthony Skehan Medicine Professional Corporation</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Male Health Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ultra-Med Inc</name>
      <address>
        <city>Point-Claire</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologie, Male namesti 1783</name>
      <address>
        <city>Benesov</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urocentrum Brno, Purkynova 35e</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prvni privatni chirurgicke centrum SANUS, Labská kotlina I/1220</name>
      <address>
        <city>Hradec Králové</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologicka ambulance, Litomerice (Halek)</name>
      <address>
        <city>Litomerice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slezska nemocnice, prospevkova organizace, Urologicke oddeleni</name>
      <address>
        <city>Opava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Androgeos - soukrome urologicke a andrologicke cen, Na valech 4/289</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urocentrum, Karlovo namesti 3</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologica ambulance, Praha 10</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ústecké urocentrum, Ústi nad Labem (Liehne)</name>
      <address>
        <city>Ústi nad Labem</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologia, A.O. San Giuseppe Moscati, Avellino</name>
      <address>
        <city>Avellino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa di Urologia, Azienda Opsedaliera Luigi Sacco</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa di Urologia, Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademia Medyczna w Gdansku</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Publiczny Specjalistyczny ZOZ</name>
      <address>
        <city>Inowroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny nr.1</name>
      <address>
        <city>Zabrze</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Denmark</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2009</study_first_submitted>
  <study_first_submitted_qc>July 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2009</study_first_posted>
  <results_first_submitted>April 22, 2014</results_first_submitted>
  <results_first_submitted_qc>April 28, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 14, 2015</results_first_posted>
  <disposition_first_submitted>March 9, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>March 9, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 14, 2012</disposition_first_posted>
  <last_update_submitted>May 13, 2015</last_update_submitted>
  <last_update_submitted_qc>May 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients who met the eligibility criteria were randomised in a 1:1:1:1 manner to 1 of the 4 treatment groups in this trial. The randomisation was stratified by region (North America and Europe) and prostate volume (&lt;30 mL and ≥30 mL). 404 patients were randomised and received a single dose of placebo, 10 mg, 20 mg, or 30 mg degarelix.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo: Mannitol 50 mg/mL solution. The dose was administered as a subcutaneous (s.c.) injection in the abdominal region.</description>
        </group>
        <group group_id="P2">
          <title>Degarelix 10 mg</title>
          <description>Degarelix 10 mg: 10 mg degarelix, 40 mg/mL solution. The dose was administered as a s.c. injection in the abdominal region.</description>
        </group>
        <group group_id="P3">
          <title>Degarelix 20 mg</title>
          <description>Degarelix 20 mg: 20 mg degarelix, 40 mg/mL solution. The dose was administered as a s.c. injection in the abdominal region.</description>
        </group>
        <group group_id="P4">
          <title>Degarelix 30 mg</title>
          <description>Degarelix 30 mg: 30 mg degarelix, 40 mg/mL solution. The dose was administered as a s.c. injection in the abdominal region.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100">Started: Randomised.</participants>
                <participants group_id="P2" count="101"/>
                <participants group_id="P3" count="101"/>
                <participants group_id="P4" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set (FAS)</title>
              <participants_list>
                <participants group_id="P1" count="100">FAS: Received a dose of IMP and completed at least one post-baseline IPSS questionnaire.</participants>
                <participants group_id="P2" count="101"/>
                <participants group_id="P3" count="100">1 patient received 20 mg degarelix but had no post-baseline IPSS value and was excluded from the FAS</participants>
                <participants group_id="P4" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Actual Treatment</title>
              <participants_list>
                <participants group_id="P1" count="98">2 placebo patients received 30 mg degarelix</participants>
                <participants group_id="P2" count="101"/>
                <participants group_id="P3" count="100">1 patient randomised to 20 mg degarelix received 30 mg degarelix</participants>
                <participants group_id="P4" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="98">Safety Analysis Set: Received a dose of Investigational Medicinal Product (IMP).</participants>
                <participants group_id="P2" count="101"/>
                <participants group_id="P3" count="100"/>
                <participants group_id="P4" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Visit 12, Month 6</title>
              <participants_list>
                <participants group_id="P1" count="93">The trial was stopped when all patients had completed Visit 12, scheduled 6 months after the dosing.</participants>
                <participants group_id="P2" count="91"/>
                <participants group_id="P3" count="90"/>
                <participants group_id="P4" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26">End of Trial, Month 12: Patients who had completed the 12-month period when the trial was stopped.</participants>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="77"/>
                <participants group_id="P3" count="79"/>
                <participants group_id="P4" count="82"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other/Unknown</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Trial Terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="61"/>
                <participants group_id="P3" count="62"/>
                <participants group_id="P4" count="70"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>FAS. The efficacy analyses were based on the “as planned” treatment. Three patients deviated from the planned dosing and were included in the planned treatment groups in the FAS (i.e. not in the actual treatment groups as for the Safety Analysis Set).</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo: Mannitol 50 mg/mL solution. The dose was administered as a s.c. injection in the abdominal region.</description>
        </group>
        <group group_id="B2">
          <title>Degarelix 10 mg</title>
          <description>Degarelix 10 mg: 10 mg degarelix, 40 mg/mL solution. The dose was administered as a s.c. injection in the abdominal region.</description>
        </group>
        <group group_id="B3">
          <title>Degarelix 20 mg</title>
          <description>Degarelix 20 mg: 20 mg degarelix, 40 mg/mL solution. The dose was administered as a s.c. injection in the abdominal region.</description>
        </group>
        <group group_id="B4">
          <title>Degarelix 30 mg</title>
          <description>Degarelix 30 mg: 30 mg degarelix, 40 mg/mL solution. The dose was administered as a s.c. injection in the abdominal region.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="101"/>
            <count group_id="B3" value="100"/>
            <count group_id="B4" value="102"/>
            <count group_id="B5" value="403"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.2" spread="7.86"/>
                    <measurement group_id="B2" value="64.9" spread="7.89"/>
                    <measurement group_id="B3" value="65.7" spread="7.12"/>
                    <measurement group_id="B4" value="65.4" spread="7.56"/>
                    <measurement group_id="B5" value="65.3" spread="7.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="102"/>
                    <measurement group_id="B5" value="403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="98"/>
                    <measurement group_id="B5" value="394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="96"/>
                    <measurement group_id="B4" value="96"/>
                    <measurement group_id="B5" value="384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="60"/>
                    <measurement group_id="B5" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Body Mass Index (BMI)</title>
          <units>(kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.5" spread="3.66"/>
                    <measurement group_id="B2" value="28.4" spread="3.93"/>
                    <measurement group_id="B3" value="27.9" spread="3.84"/>
                    <measurement group_id="B4" value="28.2" spread="4.81"/>
                    <measurement group_id="B5" value="28.2" spread="4.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline International Prostate Symptom Scores (IPSS)</title>
          <description>The IPSS questionnaire was used to assess the severity of Lower Urinary Tract Symptoms (LUTS). A detailed description of the questionnaire is provided in the Primary Outcome Measure section.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.1" spread="4.38"/>
                    <measurement group_id="B2" value="19.9" spread="5.21"/>
                    <measurement group_id="B3" value="19.6" spread="4.42"/>
                    <measurement group_id="B4" value="19.8" spread="4.88"/>
                    <measurement group_id="B5" value="19.6" spread="4.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Total Prostate Volume (TPV)</title>
          <description>TPV was measured directly by Trans-Rectal Ultrasound (TRUS).</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.6" spread="17.8"/>
                    <measurement group_id="B2" value="42.9" spread="18.8"/>
                    <measurement group_id="B3" value="42.3" spread="20.2"/>
                    <measurement group_id="B4" value="42.1" spread="20.2"/>
                    <measurement group_id="B5" value="42.2" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Maximum Urinary Flow (Qmax)</title>
          <description>Uroflowmetry was used according to International Continence Society (ICS) recommendation.</description>
          <units>mL/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.2" spread="2.51"/>
                    <measurement group_id="B2" value="10.3" spread="2.65"/>
                    <measurement group_id="B3" value="10.6" spread="4.58"/>
                    <measurement group_id="B4" value="10.2" spread="2.44"/>
                    <measurement group_id="B5" value="10.3" spread="3.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in International Prostate Symptom Score (IPSS)</title>
        <description>This outcome measure was used to assess the dose-response of the 3 degarelix dose groups in terms of severity of lower urinary tract symptoms (LUTS) and progress of the disease process, versus the placebo group. One treatment month equals 28 days.
The IPSS questionnaire is a tool commonly used to assess the severity of LUTS, and to monitor the progress of the symptoms during treatment. It contains 7 questions regarding incomplete emptying, frequency, intermittency, urgency, weak stream, straining, and nocturia. Each question is assigned a score of 0-5 (i.e. minimum total score is 0 and the maximum score is 35), where &quot;0&quot; corresponds to a response of &quot;not at all&quot; for the first six symptoms and &quot;none&quot; for nocturia, and &quot;5&quot; corresponds to a response of &quot;almost always&quot; for the first six symptoms and &quot;5 times or more&quot; for nocturia. The IPSS also includes a question to evaluate a patient's quality of life in relation to his urinary symptoms, which is not included in the total IPSS score.</description>
        <time_frame>From Baseline to Month 3 after Dosing</time_frame>
        <population>FAS. The &quot;as planned&quot; patient allocation for treatment groups was used in the efficacy analyses (please refer to the Baseline Characteristics section).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Mannitol 50 mg/mL solution. The dose was administered as a subcutaneous (s.c.) injection in the abdominal region.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 10 mg</title>
            <description>Degarelix 10 mg: 10 mg degarelix, 40 mg/mL solution. The dose was administered as a subcutaneous (s.c.) injection in the abdominal region.</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 20 mg</title>
            <description>Degarelix 20 mg: 20 mg degarelix, 40 mg/mL solution. The dose was administered as a s.c. injection in the abdominal region.</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 30 mg</title>
            <description>Degarelix 30 mg: 30 mg degarelix, 40 mg/mL solution. The dose was administered as a s.c. injection in the abdominal region.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in International Prostate Symptom Score (IPSS)</title>
          <description>This outcome measure was used to assess the dose-response of the 3 degarelix dose groups in terms of severity of lower urinary tract symptoms (LUTS) and progress of the disease process, versus the placebo group. One treatment month equals 28 days.
The IPSS questionnaire is a tool commonly used to assess the severity of LUTS, and to monitor the progress of the symptoms during treatment. It contains 7 questions regarding incomplete emptying, frequency, intermittency, urgency, weak stream, straining, and nocturia. Each question is assigned a score of 0-5 (i.e. minimum total score is 0 and the maximum score is 35), where &quot;0&quot; corresponds to a response of &quot;not at all&quot; for the first six symptoms and &quot;none&quot; for nocturia, and &quot;5&quot; corresponds to a response of &quot;almost always&quot; for the first six symptoms and &quot;5 times or more&quot; for nocturia. The IPSS also includes a question to evaluate a patient's quality of life in relation to his urinary symptoms, which is not included in the total IPSS score.</description>
          <population>FAS. The &quot;as planned&quot; patient allocation for treatment groups was used in the efficacy analyses (please refer to the Baseline Characteristics section).</population>
          <units>percentage change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.46" spread="5.34"/>
                    <measurement group_id="O2" value="-5.65" spread="6.03"/>
                    <measurement group_id="O3" value="-6.11" spread="5.7"/>
                    <measurement group_id="O4" value="-5.88" spread="5.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis of Covariance (ANCOVA) of the change from baseline in IPSS at Month 3 in the FAS population using the Last Observation Carried Forward (LOCF) method, including the baseline IPSS as adjusting covariate and treatment group, prostate volume stratum (&lt;30 mL and ≥30 mL), and region (North America and Europe) as factors.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0911</p_value>
            <p_value_desc>P-value based on Williams' extended trend test of comparison vs. placebo at Month 3. No adjustment for multiple comparisons was made.</p_value_desc>
            <method>Step-down, Williams' extended trend test</method>
            <method_desc>Step-down procedure (starting with 30 mg vs. placebo) to identify the minimum effective dose. The step-down testing protects the type I error rate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.30</param_value>
            <estimate_desc>Treatment difference between &quot;Degarelix 30 mg&quot; and &quot;Placebo&quot; at Month 3.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis of Covariance (ANCOVA) of the change from baseline in IPSS at Month 3 in the FAS population using the Last Observation Carried Forward (LOCF) method, including the baseline IPSS as adjusting covariate and treatment group, prostate volume stratum (&lt;30 mL and ≥30 mL), and region (North America and Europe) as factors.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0865</p_value>
            <p_value_desc>P-value based on Williams' extended trend test of comparison vs. placebo at Month 3. No adjustment for multiple comparisons was made.</p_value_desc>
            <method>Step-down, Williams' extended trend test</method>
            <method_desc>Step-down procedure (starting with 30 mg vs. placebo) to identify the minimum effective dose. The step-down testing protects the type I error rate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.44</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Treatment difference between &quot;Degarelix 20 mg&quot; and &quot;Placebo&quot; at Month 3.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of Covariance (ANCOVA) of the change from baseline in IPSS at Month 3 in the FAS population using the Last Observation Carried Forward (LOCF) method, including the baseline IPSS as adjusting covariate and treatment group, prostate volume stratum (&lt;30 mL and ≥30 mL), and region (North America and Europe) as factors.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2342</p_value>
            <p_value_desc>P-value based on Williams' extended trend test of comparison vs. placebo at Month 3. No adjustment for multiple comparisons was made.</p_value_desc>
            <method>Step-down, Williams' extended trend test</method>
            <method_desc>Step-down procedure (starting with 30 mg vs. placebo) to identify the minimum effective dose. The step-down testing protects the type I error rate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.92</param_value>
            <estimate_desc>Treatment difference between &quot;Degarelix 10 mg&quot; and &quot;Placebo&quot; at Month 3.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in IPSS</title>
        <description>This secondary outcome measure was used to assess the maintained dose-response of the 3 degarelix dose groups in terms of severity of LUTS and progress of the disease process, versus the placebo group.</description>
        <time_frame>From Baseline to Month 4, Month 5 and Month 6 after Dosing</time_frame>
        <population>FAS. The &quot;as planned&quot; patient allocation for treatment groups was used (please refer to the Baseline Characteristics section).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Mannitol 50 mg/mL solution. The dose was administered as a subcutaneous (s.c.) injection in the abdominal region.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 10 mg</title>
            <description>Degarelix 10 mg: 10 mg degarelix, 40 mg/mL solution. The dose was administered as a s.c. injection in the abdominal region.</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 20 mg</title>
            <description>Degarelix 20 mg: 20 mg degarelix, 40 mg/mL solution. The dose was administered as a s.c. injection in the abdominal region.</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 30 mg</title>
            <description>Degarelix 30 mg: 30 mg degarelix, 40 mg/mL solution. The dose was administered as a s.c. injection in the abdominal region.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in IPSS</title>
          <description>This secondary outcome measure was used to assess the maintained dose-response of the 3 degarelix dose groups in terms of severity of LUTS and progress of the disease process, versus the placebo group.</description>
          <population>FAS. The &quot;as planned&quot; patient allocation for treatment groups was used (please refer to the Baseline Characteristics section).</population>
          <units>percentage change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean Percentage Change at Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.12" spread="5.65"/>
                    <measurement group_id="O2" value="-5.52" spread="6.18"/>
                    <measurement group_id="O3" value="-6.3" spread="6.38"/>
                    <measurement group_id="O4" value="-5.64" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Percentage Change at Month 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.34" spread="5.94"/>
                    <measurement group_id="O2" value="-5.59" spread="6.89"/>
                    <measurement group_id="O3" value="-6.1" spread="6.46"/>
                    <measurement group_id="O4" value="-5.37" spread="5.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Percentage Change at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="5.47"/>
                    <measurement group_id="O2" value="-5.42" spread="6.7"/>
                    <measurement group_id="O3" value="-5.72" spread="5.59"/>
                    <measurement group_id="O4" value="-5.62" spread="5.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>ANCOVA of the change from baseline in IPSS at Months 4 in the FAS population using the LOCF method, including the baseline IPSS as adjusting covariate and treatment group, prostate volume stratum (&lt;30 mL and ≥30 mL), and region (North America and Europe) as factors.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0367</p_value>
            <p_value_desc>P-values based on Williams' extended trend test of comparison vs. placebo at Month 4. No adjustment for multiple comparisons was made.</p_value_desc>
            <method>Step-down, Williams' extended trend test</method>
            <method_desc>Step-down procedure (starting with 30 mg vs. placebo) to identify the minimum effective dose. The step-down testing protects the type I error rate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.62</param_value>
            <estimate_desc>Treatment difference between &quot;Degarelix 30 mg&quot; and &quot;Placebo&quot; at Month 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ANCOVA of the change from baseline in IPSS at Month 4 in the FAS population using the LOCF method, including the baseline IPSS as adjusting covariate and treatment group, prostate volume stratum (&lt;30 mL and ≥30 mL), and region (North America and Europe) as factors.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0231</p_value>
            <p_value_desc>P-value based on Williams' extended trend test of comparison vs. placebo at Month 4. No adjustment for multiple comparisons was made.</p_value_desc>
            <method>Step-down, Williams' extended trend test</method>
            <method_desc>Step-down procedure (starting with 30 mg vs. placebo) to identify the minimum effective dose. The step-down testing protects the type I error rate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.97</param_value>
            <estimate_desc>Treatment difference between &quot;Degarelix 20 mg&quot; and &quot;Placebo&quot; at Month 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ANCOVA of the change from baseline in IPSS at Month 4 in the FAS population using the LOCF method, including the baseline IPSS as adjusting covariate and treatment group, prostate volume stratum (&lt;30 mL and ≥30 mL), and region (North America and Europe) as factors.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1638</p_value>
            <p_value_desc>P-value based on Williams' extended trend test of comparison vs. placebo at Month 4. No adjustment for multiple comparisons was made.</p_value_desc>
            <method>Step-down, Williams' extended trend test</method>
            <method_desc>Step-down procedure (starting with 30 mg vs. placebo) to identify the minimum effective dose. The step-down testing protects the type I error rate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.11</param_value>
            <estimate_desc>Treatment difference between &quot;Degarelix 10 mg&quot; and &quot;Placebo&quot; at Month 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>ANCOVA of the change from baseline in IPSS at Month 5 in the FAS population using the LOCF method, including the baseline IPSS as adjusting covariate and treatment group, prostate volume stratum (&lt;30 mL and ≥30 mL), and region (North America and Europe) as factors.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1941</p_value>
            <p_value_desc>P-values based on Williams' extended trend test of comparisons vs. placebo at Month 5. No adjustment for multiple comparison was made.</p_value_desc>
            <method>Step-down, Williams' extended trend test</method>
            <method_desc>Step-down procedure (starting with 30 mg vs. placebo) to identify the minimum effective dose. The step-down testing protects the type I error rate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.14</param_value>
            <estimate_desc>Treatment difference between &quot;Degarelix 30 mg&quot; and &quot;Placebo&quot; at Month 5.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ANCOVA of the change from baseline in IPSS at Month 5 in the FAS population using the LOCF method, including the baseline IPSS as adjusting covariate and treatment group, prostate volume stratum (&lt;30 mL and ≥30 mL), and region (North America and Europe) as factors.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1083</p_value>
            <p_value_desc>P-value based on Williams' extended trend test of comparison vs. placebo at Month 5. No adjustment for multiple comparisons was made.</p_value_desc>
            <method>Step-down, Williams' extended trend test</method>
            <method_desc>Step-down procedure (starting with 30 mg vs. placebo) to identify the minimum effective dose. The step-down testing protects the type I error rate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.54</param_value>
            <estimate_desc>Treatment difference between &quot;Degarelix 20 mg&quot; and &quot;Placebo&quot; at Month 5.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ANCOVA of the change from baseline in IPSS at Month 5 in the FAS population using the LOCF method, including the baseline IPSS as adjusting covariate and treatment group, prostate volume stratum (&lt;30 mL and ≥30 mL), and region (North America and Europe) as factors.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2782</p_value>
            <p_value_desc>P-value based on Williams' extended trend test of comparison vs. placebo at Month 5. No adjustment for multiple comparisons was made.</p_value_desc>
            <method>Step-down, Williams' extended trend test</method>
            <method_desc>Step-down procedure (starting with 30 mg vs. placebo) to identify the minimum effective dose. The step-down testing protects the type I error rate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.95</param_value>
            <estimate_desc>Treatment difference between &quot;Degarelix 10 mg&quot; and &quot;Placebo&quot; at Month 5.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>ANCOVA of the change from baseline in IPSS at Month 6 in the FAS population using the LOCF method, including the baseline IPSS as adjusting covariate and treatment group, prostate volume stratum (&lt;30 mL and ≥30 mL), and region (North America and Europe) as factors.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1562</p_value>
            <p_value_desc>P-values based on Williams' extended trend test of comparison vs. placebo at Month 6. No adjustment for multiple comparisons was made.</p_value_desc>
            <method>Step-down, Williams' extended trend test</method>
            <method_desc>Step-down procedure (starting with 30 mg vs. placebo) to identify the minimum effective dose. The step-down testing protects the type I error rate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.15</param_value>
            <estimate_desc>Treatment difference between &quot;Degarelix 30 mg&quot; and &quot;Placebo&quot; at Month 6.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ANCOVA of the change from baseline in IPSS at Month 6 in the FAS population using the LOCF method, including the baseline IPSS as adjusting covariate and treatment group, prostate volume stratum (&lt;30 mL and ≥30 mL), and region (North America and Europe) as factors.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1736</p_value>
            <p_value_desc>P-value based on Williams' extended trend test of comparison vs. placebo at Month 6. No adjustment for multiple comparisons was made.</p_value_desc>
            <method>Step-down, Williams' extended trend test</method>
            <method_desc>Step-down procedure (starting with 30 mg vs. placebo) to identify the minimum effective dose. The step-down testing protects the type I error rate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.24</param_value>
            <estimate_desc>Treatment difference between &quot;Degarelix 20 mg&quot; and &quot;Placebo&quot; at Month 6.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ANCOVA of the change from baseline in IPSS at Month 6 in the FAS population using the LOCF method, including the baseline IPSS as adjusting covariate and treatment group, prostate volume stratum (&lt;30 mL and ≥30 mL), and region (North America and Europe) as factors.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3132</p_value>
            <p_value_desc>P-value based on Williams' extended trend test of comparison vs. placebo at Month 6. No adjustment for multiple comparisons was made.</p_value_desc>
            <method>Step-down, Williams' extended trend test</method>
            <method_desc>Step-down procedure (starting with 30 mg vs. placebo) to identify the minimum effective dose. The step-down testing protects the type I error rate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.84</param_value>
            <estimate_desc>Treatment difference between &quot;Degarelix 10 mg&quot; and &quot;Placebo&quot; at Month 6.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Odds Ratio (as Compared to Placebo) of Treatment Response in IPSS</title>
        <description>A 3-point reduction in IPSS score compared to baseline is defined as a clinically meaningful treatment response. Percentage of participants who met criteria for a clinically meaningful treatment response and odds ratios of treatment responses between each degarelix dose group and the placebo group are presented.</description>
        <time_frame>At Month 3, Month 4, Month 5 and Month 6 after Dosing</time_frame>
        <population>FAS. The &quot;as planned&quot; patient allocation for treatment groups was used (please refer to the Baseline Characteristics section).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Mannitol 50 mg/mL solution. The dose was administered as a subcutaneous (s.c.) injection in the abdominal region.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 10 mg</title>
            <description>Degarelix 10 mg: 10 mg degarelix, 40 mg/mL solution. The dose was administered as a s.c. injection in the abdominal region.</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 20 mg</title>
            <description>Degarelix 20 mg: 20 mg degarelix, 40 mg/mL solution. The dose was administered as a s.c. injection in the abdominal region.</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 30 mg</title>
            <description>Degarelix 30 mg: 30 mg degarelix, 40 mg/mL solution. The dose was administered as a s.c. injection in the abdominal region.</description>
          </group>
        </group_list>
        <measure>
          <title>Odds Ratio (as Compared to Placebo) of Treatment Response in IPSS</title>
          <description>A 3-point reduction in IPSS score compared to baseline is defined as a clinically meaningful treatment response. Percentage of participants who met criteria for a clinically meaningful treatment response and odds ratios of treatment responses between each degarelix dose group and the placebo group are presented.</description>
          <population>FAS. The &quot;as planned&quot; patient allocation for treatment groups was used (please refer to the Baseline Characteristics section).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3-point reduction in IPSS vs. baseline (Month 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.0"/>
                    <measurement group_id="O2" value="72.3"/>
                    <measurement group_id="O3" value="69.0"/>
                    <measurement group_id="O4" value="68.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-point reduction in IPSS vs. baseline (Month 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.0"/>
                    <measurement group_id="O2" value="65.3"/>
                    <measurement group_id="O3" value="71.0"/>
                    <measurement group_id="O4" value="70.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-point reduction in IPSS vs. baseline (Month 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.0"/>
                    <measurement group_id="O2" value="64.4"/>
                    <measurement group_id="O3" value="66.0"/>
                    <measurement group_id="O4" value="67.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-point reduction in IPSS vs. baseline (Month 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.0"/>
                    <measurement group_id="O2" value="68.3"/>
                    <measurement group_id="O3" value="67.0"/>
                    <measurement group_id="O4" value="71.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2034</p_value>
            <p_value_desc>Adjustments were made for treatment group, baseline IPSS, graphical region (North America and Europe) and baseline prostate size (&lt;30 mL and ≥30 mL).
Unadjusted p-value of comparison vs. placebo at Month 3.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>No adjustment for multiple comparisons was made. LOCF.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.814</ci_lower_limit>
            <ci_upper_limit>2.628</ci_upper_limit>
            <estimate_desc>Odds ratio of treatment response between &quot;Degarelix 30 mg&quot; and &quot;Placebo&quot; at Month 3.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1748</p_value>
            <p_value_desc>Adjustments were made for treatment group, baseline IPSS, graphical region (North America and Europe) and baseline prostate size (&lt;30 mL and ≥30 mL).
Unadjusted p-value of comparison vs. placebo at Month 3.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>No adjustment for multiple comparisons was made. LOCF.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.834</ci_lower_limit>
            <ci_upper_limit>2.710</ci_upper_limit>
            <estimate_desc>Odds ratio of treatment response between &quot;Degarelix 20 mg&quot; and &quot;Placebo&quot; at Month 3.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0658</p_value>
            <p_value_desc>Adjustments were made for treatment group, baseline IPSS, graphical region (North America and Europe) and baseline prostate size (&lt;30 mL and ≥30 mL).
Unadjusted p-value of comparison vs. placebo at Month 3.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>No adjustment for multiple comparisons was made. LOCF.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.964</ci_lower_limit>
            <ci_upper_limit>3.195</ci_upper_limit>
            <estimate_desc>Odds ratio of treatment response between &quot;Degarelix 10 mg&quot; and &quot;Placebo&quot; at Month 3.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0587</p_value>
            <p_value_desc>Adjustments were made for treatment group, baseline IPSS, graphical region (North America and Europe) and baseline prostate size (&lt;30 mL and ≥30 mL).
Unadjusted p-value of comparison vs. placebo at Month 4.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>No adjustment for multiple comparisons was made. LOCF.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.979</ci_lower_limit>
            <ci_upper_limit>3.184</ci_upper_limit>
            <estimate_desc>Odds ratio of treatment response between &quot;Degarelix 30 mg&quot; and &quot;Placebo&quot; at Month 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0490</p_value>
            <p_value_desc>Adjustments were made for treatment group, baseline IPSS, graphical region (North America and Europe) and baseline prostate size (&lt;30 mL and ≥30 mL).
Unadjusted p-value of comparison vs. placebo at Month 4.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>No adjustment for multiple comparisons was made. LOCF.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.003</ci_lower_limit>
            <ci_upper_limit>3.283</ci_upper_limit>
            <estimate_desc>Odds ratio of treatment response between &quot;Degarelix 20 mg&quot; and &quot;Placebo&quot; at Month 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2742</p_value>
            <p_value_desc>Adjustments were made for treatment group, baseline IPSS, graphical region (North America and Europe) and baseline prostate size (&lt;30 mL and ≥30 mL).
Unadjusted p-value of comparison vs. placebo at Month 4.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>No adjustment for multiple comparisons was made. LOCF.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.774</ci_lower_limit>
            <ci_upper_limit>2.464</ci_upper_limit>
            <estimate_desc>Odds ratio of treatment response between &quot;Degarelix 10 mg&quot; and &quot;Placebo&quot; at Month 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4206</p_value>
            <p_value_desc>Adjustments were made for treatment group, baseline IPSS, graphical region (North America and Europe) and baseline prostate size (&lt;30 mL and ≥30 mL).
Unadjusted p-value of comparison vs. placebo at Month 5.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>No adjustment for multiple comparisons was made. LOCF.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.706</ci_lower_limit>
            <ci_upper_limit>2.304</ci_upper_limit>
            <estimate_desc>Odds ratio of treatment response between &quot;Degarelix 30 mg&quot; and &quot;Placebo&quot; at Month 5.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5494</p_value>
            <p_value_desc>Adjustments were made for treatment group, baseline IPSS, graphical region (North America and Europe) and baseline prostate size (&lt;30 mL and ≥30 mL).
Unadjusted p-value of comparison vs. placebo at Month 5.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>No adjustment for multiple comparisons was made. LOCF.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.664</ci_lower_limit>
            <ci_upper_limit>2.160</ci_upper_limit>
            <estimate_desc>Odds ratio of treatment response between &quot;Degarelix 20 mg&quot; and &quot;Placebo&quot; at Month 5.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7586</p_value>
            <p_value_desc>Adjustments were made for treatment group, baseline IPSS, graphical region (North America and Europe) and baseline prostate size (&lt;30 mL and ≥30 mL).
Unadjusted p-value of comparison vs. placebo at Month 5.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>No adjustment for multiple comparisons was made. LOCF.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.609</ci_lower_limit>
            <ci_upper_limit>1.975</ci_upper_limit>
            <estimate_desc>Odds ratio of treatment response between &quot;Degarelix 10 mg&quot; and &quot;Placebo&quot; at Month 5.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1946</p_value>
            <p_value_desc>Adjustments were made for treatment group, baseline IPSS, graphical region (North America and Europe) and baseline prostate size (&lt;30 mL and ≥30 mL).
Unadjusted p-value of comparison vs. placebo at Month 6.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>No adjustment for multiple comparisons was made. LOCF.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.816</ci_lower_limit>
            <ci_upper_limit>2.717</ci_upper_limit>
            <estimate_desc>Odds ratio of treatment response between &quot;Degarelix 30 mg&quot; and &quot;Placebo&quot; at Month 6.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5380</p_value>
            <p_value_desc>Adjustments were made for treatment group, baseline IPSS, graphical region (North America and Europe) and baseline prostate size (&lt;30 mL and ≥30 mL).
Unadjusted p-value of comparison vs. placebo at Month 6.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>No adjustment for multiple comparisons was made. LOCF.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.667</ci_lower_limit>
            <ci_upper_limit>2.174</ci_upper_limit>
            <estimate_desc>Odds ratio of treatment response between &quot;Degarelix 20 mg&quot; and &quot;Placebo&quot; at Month 6.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4263</p_value>
            <p_value_desc>Adjustments were made for treatment group, baseline IPSS, graphical region (North America and Europe) and baseline prostate size (&lt;30 mL and ≥30 mL).
Unadjusted p-value of comparison vs. placebo at Month 6.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>No adjustment for multiple comparisons was made. LOCF.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.702</ci_lower_limit>
            <ci_upper_limit>2.308</ci_upper_limit>
            <estimate_desc>Odds ratio of treatment response between &quot;Degarelix 10 mg&quot; and &quot;Placebo&quot; at Month 6.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percentage Change in Total Prostate Volume (TPV)</title>
        <description>TPV was measured directly by standardised trans-rectal ultrasound (TRUS).</description>
        <time_frame>From Baseline to Month 3 and Month 6 after Dosing</time_frame>
        <population>FAS. The &quot;as planned&quot; patient allocation for treatment groups was used (please refer to the Baseline Characteristics section).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Mannitol 50 mg/mL solution. The dose was administered as a subcutaneous (s.c.) injection in the abdominal region.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 10 mg</title>
            <description>Degarelix 10 mg: 10 mg degarelix, 40 mg/mL solution. The dose was administered as a s.c. injection in the abdominal region.</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 20 mg</title>
            <description>Degarelix 20 mg: 20 mg degarelix, 40 mg/mL solution. The dose was administered as a s.c. injection in the abdominal region.</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 30 mg</title>
            <description>Degarelix 30 mg: 30 mg degarelix, 40 mg/mL solution. The dose was administered as a s.c. injection in the abdominal region.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage Change in Total Prostate Volume (TPV)</title>
          <description>TPV was measured directly by standardised trans-rectal ultrasound (TRUS).</description>
          <population>FAS. The &quot;as planned&quot; patient allocation for treatment groups was used (please refer to the Baseline Characteristics section).</population>
          <units>percentage change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean Percentage Change at Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.15" spread="23.3"/>
                    <measurement group_id="O2" value="-1.46" spread="32.7"/>
                    <measurement group_id="O3" value="-0.252" spread="24.5"/>
                    <measurement group_id="O4" value="0.188" spread="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Percentage Change at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.96" spread="29.3"/>
                    <measurement group_id="O2" value="1.57" spread="31"/>
                    <measurement group_id="O3" value="2.35" spread="26.5"/>
                    <measurement group_id="O4" value="-0.0112" spread="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4607</p_value>
            <p_value_desc>No adjustment for multiple comparisons was made. Unadjusted p-value of comparison vs. placebo at Month 3.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline TPV as covariate and treatment group, region (North America,Europe) and prostate volume stratum (&lt;30 mL,≥30 mL) as factors. LOCF.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.113</ci_lower_limit>
            <ci_upper_limit>4.590</ci_upper_limit>
            <estimate_desc>Treatment difference between &quot;Degarelix 30 mg&quot; and &quot;Placebo&quot; at Month 3.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3876</p_value>
            <p_value_desc>No adjustment for multiple comparisons was made. Unadjusted p-value of comparison vs. placebo at Month 3.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline TPV as covariate and treatment group, region (North America,Europe) and prostate volume stratum (&lt;30 mL,≥30 mL) as factors. LOCF.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.614</ci_lower_limit>
            <ci_upper_limit>4.128</ci_upper_limit>
            <estimate_desc>Treatment difference between &quot;Degarelix 20 mg&quot; and &quot;Placebo&quot; at Month 3.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2548</p_value>
            <p_value_desc>No adjustment for multiple comparisons was made. Unadjusted p-value of comparison vs. placebo at Month 3.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline TPV as covariate and treatment group, region (North America,Europe) and prostate volume stratum (&lt;30 mL,≥30 mL) as factors. LOCF.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.650</ci_lower_limit>
            <ci_upper_limit>3.096</ci_upper_limit>
            <estimate_desc>Treatment difference between &quot;Degarelix 10 mg&quot; and &quot;Placebo&quot; at Month 3.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5652</p_value>
            <p_value_desc>No adjustment for multiple comparisons was made. Unadjusted p-value of comparison vs. placebo at Month 6.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline TPV as covariate and treatment group, region (North America,Europe) and prostate volume stratum (&lt;30 mL,≥30 mL) as factors. LOCF.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.729</ci_lower_limit>
            <ci_upper_limit>5.322</ci_upper_limit>
            <estimate_desc>Treatment difference between &quot;Degarelix 30 mg&quot; and &quot;Placebo&quot; at Month 6.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7502</p_value>
            <p_value_desc>No adjustment for multiple comparisons was made. Unadjusted p-value of comparison vs. placebo at Month 6.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline TPV as covariate and treatment group, region (North America,Europe) and prostate volume stratum (&lt;30 mL,≥30 mL) as factors. LOCF.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.768</ci_lower_limit>
            <ci_upper_limit>6.322</ci_upper_limit>
            <estimate_desc>Treatment difference between &quot;Degarelix 20 mg&quot; and &quot;Placebo&quot; at Month 6.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6089</p_value>
            <p_value_desc>No adjustment for multiple comparisons was made. Unadjusted p-value of comparison vs. placebo at Month 6.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline TPV as covariate and treatment group, region (North America,Europe) and prostate volume stratum (&lt;30 mL,≥30 mL) as factors. LOCF.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.513</ci_lower_limit>
            <ci_upper_limit>5.581</ci_upper_limit>
            <estimate_desc>Treatment difference between &quot;Degarelix 10 mg&quot; and &quot;Placebo&quot; at Month 6.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Maximum Urinary Flow (Qmax)</title>
        <description>Urinary flow rate (mL/second) was measured using uroflowmetry performed according to the recommendation from the International Continence Society (ICS).</description>
        <time_frame>From Baseline to Month 3 and Month 6 after Dosing</time_frame>
        <population>FAS. The &quot;as planned&quot; patient allocation for treatment groups was used (please refer to the Baseline Characteristics section).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Mannitol 50 mg/mL solution. The dose was administered as a subcutaneous (s.c.) injection in the abdominal region.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 10 mg</title>
            <description>Degarelix 10 mg: 10 mg degarelix, 40 mg/mL solution. The dose was administered as a s.c. injection in the abdominal region.</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 20 mg</title>
            <description>Degarelix 20 mg: 20 mg degarelix, 40 mg/mL solution. The dose was administered as a s.c. injection in the abdominal region.</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 30 mg</title>
            <description>Degarelix 30 mg: 30 mg degarelix, 40 mg/mL solution. The dose was administered as a s.c. injection in the abdominal region.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Maximum Urinary Flow (Qmax)</title>
          <description>Urinary flow rate (mL/second) was measured using uroflowmetry performed according to the recommendation from the International Continence Society (ICS).</description>
          <population>FAS. The &quot;as planned&quot; patient allocation for treatment groups was used (please refer to the Baseline Characteristics section).</population>
          <units>percentage change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean Percentage Change at Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.652" spread="3.8"/>
                    <measurement group_id="O2" value="0.564" spread="5.08"/>
                    <measurement group_id="O3" value="0.626" spread="5.68"/>
                    <measurement group_id="O4" value="0.723" spread="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Percentage Change at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" spread="5.34"/>
                    <measurement group_id="O2" value="0.516" spread="4.85"/>
                    <measurement group_id="O3" value="0.582" spread="5.43"/>
                    <measurement group_id="O4" value="1.43" spread="5.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8511</p_value>
            <p_value_desc>No adjustment for multiple comparisons was made. Unadjusted p-value of comparison vs. placebo at Month 3.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline Qmax as covariate and treatment group, region (North America,Europe) and prostate volume stratum (&lt;30 mL,≥30 mL) as factors.LOCF.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.068</ci_lower_limit>
            <ci_upper_limit>1.294</ci_upper_limit>
            <estimate_desc>Treatment difference between &quot;Degarelix 30 mg&quot; and &quot;Placebo&quot; at Month 3.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6331</p_value>
            <p_value_desc>No adjustment for multiple comparisons was made. Unadjusted p-value of comparison vs. placebo at Month 3.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline Qmax as covariate and treatment group, region (North America,Europe) and prostate volume stratum (&lt;30 mL,≥30 mL) as factors.LOCF.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.900</ci_lower_limit>
            <ci_upper_limit>1.477</ci_upper_limit>
            <estimate_desc>Treatment difference between &quot;Degarelix 20 mg&quot; and &quot;Placebo&quot; at Month 3.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9090</p_value>
            <p_value_desc>No adjustment for multiple comparisons was made. Unadjusted p-value of comparison vs. placebo at Month 3.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline Qmax as covariate and treatment group, region (North America,Europe) and prostate volume stratum (&lt;30 mL,≥30 mL) as factors.LOCF.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.113</ci_lower_limit>
            <ci_upper_limit>1.250</ci_upper_limit>
            <estimate_desc>Treatment difference between &quot;Degarelix 10 mg&quot; and &quot;Placebo&quot; at Month 3.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5469</p_value>
            <p_value_desc>No adjustment for multiple comparisons was made. Unadjusted p-value of comparison vs. placebo at Month 6.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline Qmax as covariate and treatment group, region (North America,Europe) and prostate volume stratum (&lt;30 mL,≥30 mL) as factors.LOCF.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.956</ci_lower_limit>
            <ci_upper_limit>1.802</ci_upper_limit>
            <estimate_desc>Treatment difference between &quot;Degarelix 30 mg&quot; and &quot;Placebo&quot; at Month 6.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7906</p_value>
            <p_value_desc>No adjustment for multiple comparisons was made. Unadjusted p-value of comparison vs. placebo at Month 6.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline Qmax as covariate and treatment group, region (North America,Europe) and prostate volume stratum (&lt;30 mL,≥30 mL) as factors.LOCF.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.576</ci_lower_limit>
            <ci_upper_limit>1.200</ci_upper_limit>
            <estimate_desc>Treatment difference between &quot;Degarelix 20 mg&quot; and &quot;Placebo&quot; at Month 6.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5757</p_value>
            <p_value_desc>No adjustment for multiple comparisons was made. Unadjusted p-value of comparison vs. placebo at Month 6.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline Qmax as covariate and treatment group, region (North America,Europe) and prostate volume stratum (&lt;30 mL,≥30 mL) as factors.LOCF.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.773</ci_lower_limit>
            <ci_upper_limit>0.987</ci_upper_limit>
            <estimate_desc>Treatment difference between &quot;Degarelix 10 mg&quot; and &quot;Placebo&quot; at Month 6.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>This was a single dose trial and adverse events were recorded from signed informed consent up to a maximum of 12 months after the dose. However, the trial was stopped when all patients had completed the visit scheduled 6 months after the dosing.</time_frame>
      <desc>Adverse events were evaluated at each visit. The safety analyses were based on the actual treatment. Three patients did not receive their randomised treatment: 2 patients randomised to placebo received 30 mg, and 1 patient randomised to 20 mg received 30 mg degarelix. They were included in the actual treatment group in the safety analysis set.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo: Mannitol 50 mg/mL solution. The dose was administered as a s.c. injection in the abdominal region.</description>
        </group>
        <group group_id="E2">
          <title>Degarelix 10 mg</title>
          <description>Degarelix 10 mg: 10 mg degarelix, 40 mg/mL solution. The dose was administered as a s.c. injection in the abdominal region.</description>
        </group>
        <group group_id="E3">
          <title>Degarelix 20 mg</title>
          <description>Degarelix 20 mg: 20 mg degarelix, 40 mg/mL solution. The dose was administered as a s.c. injection in the abdominal region.</description>
        </group>
        <group group_id="E4">
          <title>Degarelix 30 mg</title>
          <description>Degarelix 30 mg: 30 mg degarelix, 40 mg/mL solution. The dose was administered as a s.c. injection in the abdominal region.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Coagulation time prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenosquamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid sinus syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="56" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="101"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="100"/>
                <counts group_id="E4" events="18" subjects_affected="18" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="100"/>
                <counts group_id="E4" events="19" subjects_affected="18" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="101"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="100"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="101"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="101"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="101"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="101"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="101"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="101"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="101"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E4" events="10" subjects_affected="8" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Following the planned 6-month interim analysis when all patients had completed the visit scheduled 6 months after dosing, a decision was taken to stop the trial since the primary efficacy endpoint was not met.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clinical Development Support</name_or_title>
      <organization>Ferring Pharmaceuticals</organization>
      <email>DK0-Disclosure@ferring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

